The aim of this study was to explore the relationship between statin use and the risk of pancreatic cancer.
Electronic databases were searched to identify relevant studies published until January 2018. The pooled relative risks (RRs) and 95% confidence intervals (CIs) were calculated with random-effects model. Subgroup analyses and sensitivity analysis were also conducted. Cochran Q test and I 2 statistic were used to evaluate the heterogeneity.
Twenty-six studies were included that contained more than 3 million participants and 170,000 pancreatic cancer patients. The overall result demonstrated a significant decrease in pancreatic cancer risk with statin use (RR, 0.84; 95% CI, 0.73–0.97; P = 0.000; I 2 = 84.4%). In subgroup analyses, nonsignificant association was detected between long-term statin use and the risk of pancreatic cancer (RR, 0.98; 95% CI, 0.86–1.11; P = 0.718; I 2 = 0.0%). Meanwhile, there was nonsignificant association between the use of lipophilic statins and the risk of pancreatic cancer (RR, 0.98; 95% CI, 0.84–1.15; P = 0.853; I 2 = 27.2%). No publication bias was found in this meta-analysis.
The overall result of this meta-analysis supports the hypothesis that statins have a protective effect on pancreatic cancer. Furthermore, high-quality randomized clinical trials and cohort studies are needed to confirm these findings.
From the *Department of Epidemiology and Health Statistics, School of Public Health, and
†Center for Evidence-Based Practice, Anhui Medical University; and
‡Department of Hospital Infection Prevention and Control, the Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Received for publication April 23, 2018; accepted November 10, 2018.
Address correspondence to: Yehuan Sun, MD, PhD, Department of Epidemiology and Health Statistics, School of Public Health, Anhui Medical University, No. 81 Meishan Road, Hefei, Anhui 230032, China (e-mail: firstname.lastname@example.org).
Y.Z. and M.L. contributed equally to this work.
All authors checked and reviewed the manuscript.
This study was compliant with ethical standards.
The authors declare no conflict of interest.